Roffman Miller Associates Inc. PA lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 12.9% during the third quarter, Holdings Channel reports. The fund owned 11,539 shares of the biopharmaceutical company’s stock after selling 1,709 shares during the period. Roffman Miller Associates Inc. PA’s holdings in Pfizer were worth $391,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Emerald Acquisition Ltd. acquired a new stake in shares of Pfizer during the second quarter worth about $555,074,000. Vanguard Group Inc. boosted its stake in shares of Pfizer by 1.6% in the second quarter. Vanguard Group Inc. now owns 383,339,513 shares of the biopharmaceutical company’s stock worth $13,497,386,000 after buying an additional 6,193,821 shares during the last quarter. Eaton Vance Management boosted its stake in shares of Pfizer by 154.8% in the second quarter. Eaton Vance Management now owns 9,636,949 shares of the biopharmaceutical company’s stock worth $339,317,000 after buying an additional 5,854,244 shares during the last quarter. Jana Partners LLC boosted its stake in shares of Pfizer by 46.8% in the first quarter. Jana Partners LLC now owns 13,460,304 shares of the biopharmaceutical company’s stock worth $398,963,000 after buying an additional 4,291,486 shares during the last quarter. Finally, ING Groep NV acquired a new stake in shares of Pfizer during the second quarter worth about $141,714,000. 69.48% of the stock is currently owned by institutional investors and hedge funds.
Shares of Pfizer Inc. (NYSE:PFE) traded up 0.86% during midday trading on Friday, reaching $31.69. 10,452,948 shares of the company traded hands. The company has a market capitalization of $192.31 billion, a PE ratio of 31.82 and a beta of 0.90. The company has a 50 day moving average price of $32.01 and a 200 day moving average price of $34.15. Pfizer Inc. has a 1-year low of $28.25 and a 1-year high of $37.39.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by $0.01. The company earned $13.05 billion during the quarter, compared to analysts’ expectations of $13.05 billion. Pfizer had a net margin of 13.09% and a return on equity of 23.68%. Pfizer’s quarterly revenue was up 7.9% on a year-over-year basis. During the same period last year, the firm earned $0.60 earnings per share. On average, analysts expect that Pfizer Inc. will post $2.41 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be given a $0.30 dividend. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 annualized dividend and a yield of 3.79%. Pfizer’s dividend payout ratio (DPR) is 106.20%.
PFE has been the subject of a number of recent analyst reports. Vetr upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.08 price target for the company in a research report on Tuesday, August 2nd. JPMorgan Chase & Co. set a $40.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, August 3rd. Argus restated a “buy” rating and set a $39.00 price target on shares of Pfizer in a research report on Tuesday, October 4th. Credit Suisse Group AG restated an “outperform” rating and set a $40.00 price target on shares of Pfizer in a research report on Monday, August 22nd. Finally, Bank of America Corp. restated a “buy” rating and set a $36.00 price target (down from $40.00) on shares of Pfizer in a research report on Monday, November 7th. Thirteen equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $37.73.
In other news, insider Anthony J. Maddaluna sold 10,000 shares of the business’s stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $33.00, for a total value of $330,000.00. Following the completion of the sale, the insider now owns 112,087 shares in the company, valued at approximately $3,698,871. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Albert Bourla sold 18,390 shares of the business’s stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $30.05, for a total transaction of $552,619.50. Following the completion of the sale, the insider now owns 149,199 shares of the company’s stock, valued at approximately $4,483,429.95. The disclosure for this sale can be found here. 0.07% of the stock is currently owned by company insiders.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.